Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein.

Luo J, Zheng D, Zhang W, Fang F, Wang H, Sun Y, Ding Y, Xu C, Chen Q, Zhang H, Huang D, Sun B, Chen Z.

Virol J. 2012 Nov 23;9:286. doi: 10.1186/1743-422X-9-286.

2.

Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.

Zheng M, Liu F, Shen Y, Wang S, Xu W, Fang F, Sun B, Xie Z, Chen Z.

Hum Vaccin Immunother. 2015;11(2):397-406. doi: 10.4161/21645515.2014.995056.

3.

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.

Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, Kong WP, Tumpey TM, Epstein SL.

Vaccine. 2008 Apr 16;26(17):2062-72. doi: 10.1016/j.vaccine.2008.02.047. Epub 2008 Mar 13.

PMID:
18378366
4.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

5.

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

Straight TM, Ottolini MG, Prince GA, Eichelberger MC.

Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44.

6.
7.

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Fang F, Zheng M, Chen Z.

Vaccine. 2010 Nov 10;28(48):7690-8. doi: 10.1016/j.vaccine.2010.09.019. Epub 2010 Sep 24.

PMID:
20870054
8.

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A.

PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898. Epub 2012 Jan 27.

9.

Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.

Staneková Z, Király J, Stropkovská A, Mikušková T, Mucha V, Kostolanský F, Varečková E.

Acta Virol. 2011;55(1):61-7.

PMID:
21434706
10.

Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.

Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, Randall TD, Lund FE, Kaminski DA.

J Virol. 2011 May;85(10):5027-35. doi: 10.1128/JVI.00150-11. Epub 2011 Mar 2.

11.

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.

Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27.

PMID:
20195654
12.

Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.

Budimir N, de Haan A, Meijerhof T, Gostick E, Price DA, Huckriede A, Wilschut J.

Influenza Other Respir Viruses. 2013 Nov;7(6):1202-9. doi: 10.1111/irv.12142. Epub 2013 Sep 16.

13.

Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.

Guo L, Zheng M, Ding Y, Li D, Yang Z, Wang H, Chen Q, Sui Z, Fang F, Chen Z.

Arch Virol. 2010 Nov;155(11):1765-75. doi: 10.1007/s00705-010-0756-3. Epub 2010 Jul 22.

PMID:
20652335
14.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
15.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK.

PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30.

16.

Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.

Chowdhury MY, Seo SK, Moon HJ, Talactac MR, Kim JH, Park ME, Son HY, Lee JS, Kim CJ.

Virol J. 2014 Feb 6;11:21. doi: 10.1186/1743-422X-11-21.

17.

Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.

Kim EH, Park HJ, Han GY, Song MK, Pereboev A, Hong JS, Chang J, Byun YH, Seong BL, Nguyen HH.

J Virol. 2014 Sep 1;88(17):9693-703. doi: 10.1128/JVI.00823-14. Epub 2014 Jun 11.

18.

Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice.

Meng S, Liu Z, Xu L, Li L, Mei S, Bao L, Deng W, Li L, Lei R, Xie L, Qin C, Zhang L.

PLoS One. 2011;6(5):e19863. doi: 10.1371/journal.pone.0019863. Epub 2011 May 20.

19.

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.

Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.

J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27.

PMID:
18789973
20.

Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.

Li R, Chowdhury MY, Kim JH, Kim TH, Pathinayake P, Koo WS, Park ME, Yoon JE, Roh JB, Hong SP, Sung MH, Lee JS, Kim CJ.

Vet Microbiol. 2015 Sep 30;179(3-4):250-63. doi: 10.1016/j.vetmic.2015.07.020. Epub 2015 Jul 17.

PMID:
26210951
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk